Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence and Prevalence of Pancreatic Cancer
4.2.2 Rising Awareness and Concern about the Disease
4.2.3 Technological Advancements and Innovation of New Products
4.3 Market Restraints
4.3.1 High Costs Associated with Treatment and Diagnosis
4.3.2 Side Effects of Pancreatic Cancer Therapy
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 By Treatment
5.1.1.1 Surgery
5.1.1.2 Chemotherapy
5.1.1.3 Radiation Therapy
5.1.1.4 Targeted Therapy
5.1.2 By Diagnostics
5.1.2.1 Imaging
5.1.2.2 Biopsy
5.1.2.3 Endoscopy
5.1.2.4 Other Diagnostic Tests
5.2 By Cancer Type
5.2.1 Exocrine Cancers
5.2.2 Endocrine Cancers
5.3 Geography
5.3.1 Asia-Pacific
5.3.1.1 China
5.3.1.2 Japan
5.3.1.3 India
5.3.1.4 Australia
5.3.1.5 South Korea
5.3.1.6 Rest of Asia-Pacific


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb
6.1.2 Canon Medical Systems
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffmann-La Roche AG
6.1.5 GE Healthcare
6.1.6 Hitachi Medical
6.1.7 Novartis AG
6.1.8 Pfizer Inc
6.1.9 Philips Healthcare
6.1.10 Siemens AG


7 MARKET OPPORTUNITIES AND FUTURE TRENDS